Modulators and mediators of kidney disease progression: new targets of prevention and treatment.
BACKGROUND
Hemodynamic (i.e. hyperfiltration) and metabolic (i.e. insulin resistance) changes are the targets of the present preventive measures of kidney disease progression. New horizons of molecular nephrology have extended the possibilities in the proliferation research.


OBJECTIVE
To review evidence on the significance of proliferative processes and the possibilities of interfering with proliferation.


METHODS
A review of experimental and clinical studies elucidating the significance of thromboxane, platelet derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta) for the proliferation and kidney disease progression.


RESULTS
Proliferation participates in the development and progression of glomerulosclerosis and interstitial fibrosis. A number of growth factors and cytokines trigger and accelerate the progression of kidney diseases. A number of PDGF antagonists (i.e. simvastatin, heparin, trapidil, tertatol and low protein diet) attenuate the kidney disease progression.


CONCLUSIONS
Even the present knowledge enables to improve further the kidney disease treatment schedules. (Tab. 3, Ref. 22.)
Dzúrik
R
R
Clinic of Pharmacotherapy, Institute of Preventive and Clinical Medicine, Bratislava, Slovakia.
Pontuch
P
P
Spustová
V
V
D018450:Disease Progression; D006801:Humans; D007674:Kidney Diseases / Q000473:pathology / Q000503:physiopathology*; D010982:Platelet-Derived Growth Factor / Q000502:physiology*; D013928:Thromboxane A2 / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000502:physiology*
D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D013928:Thromboxane A2